Vertex Acquires Alpine Immune Sciences for $4.9 Billion to Expand Kidney Disease Treatment Portfolio

The acquisition, valued at $65 per share, marks Vertex's largest deal, aiming to enhance its capabilities in autoimmune and inflammatory diseases.